myDropz has closed a series seed financing round of approximately CHF 2.5 million additional funding. The round was led by Oyster Bay Venture Capital, a venture capital firm with a focus on healthy, sustainable and functional
Tags :Walder Wyss
H&T Presspart, a division of the Heitkamp & Thumann Group, has acquired novelex from Liberta Partners. At its site in Nidau, novelex develops, industrialises and manufactures components and devices for the administration of
idverde group, specialists in the creation and landscaping of green spaces with more than 8’000 employees and branches in France, the United Kingdom, the Netherlands, Denmark and Germany, is now extending its activities to Switzerland where
Following the Spin-off, Sulzer and Medmix shares will start trading separately on the SIX Swiss Exchange. In an offering of new shares, which took place at the same time, 7 million new shares were issued in
Ringier Axel Springer Schweiz, the media production company, is expanding its Services division and has acquired Gryps Offertenportal, a company specialised in procuring products and services for SMEs, from its founders and further shareholders. The
Frontify, the provider of brand management software, has successfully raised an additional USD 50m in Series C funding, led by Revaia (formerly Gaia Capital Partners) with participation from HighSage Ventures and existing investors EQT Ventures,
Ultra Forensic Technology (UFT) has agreed to sell its Switzerland based Projectina business (Projectina) to UK-based private equity and advisory firm, Heligan Group. As a niche forensic and security-focused optical engineering business, Projectina has been
Sulzer, fluid engineering company specialising in pumping, agitation, mixing and separation technologies for fluids of all types, has successfully spun-off its Applicator Systems Division to the newly incorporated medmix, which shall be listed at SIX
Nautilus, an innovation specialist in home fitness, has entered into a definitive agreement to acquire Zurich based Vay, a company specialising in computer vision and AI technology solutions and the provider of motion detection and
Novartis has acquired Arctos Medical, adding a pre-clinical optogenetics-based AAV gene therapy program and Arctos’ proprietary technology to its ophthalmology portfolio. The acquisition underscores the Novartis commitment to finding treatments for patients with vision loss
